CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Bruker Q3 revenue tops estimates on US academic unit strength

By Reuters News


Overview

  • Scientific instruments maker's Q3 revenue rose 1.6%, slightly beating analyst expectations

  • Adjusted EPS for Q3 rose 24%, beating analyst expectations

  • Company reconfirmed full-year 2026 organic revenue growth and non-GAAP EPS guidance


Outlook

  • Bruker sees FY26 revenue of $3.52 bln to $3.56 bln, up 2.5%-3.5% yoy

  • Company expects FY26 non-GAAP EPS of $2.10 to $2.15, up 15%-17% yoy

  • Company expects revenue growth acceleration and double-digit EPS growth in FY27


Result Drivers

  • COST DISCIPLINE - Co said margin expansion and EPS growth were driven by cost discipline and execution

  • BOOKING TRENDS - Co reported continued positive booking trends and strengthening demand in most end markets, including US academic market

  • BEST SEGMENT GROWTH - Revenue growth in the BEST segment outpaced other segments, with 11.2% increase yoy


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$874 mln

$868.83 mln (12 Analysts)

Q3 Adjusted EPS

Beat

$0.56

$0.42 (12 Analysts)

Q3 Net Loss

$109.70 mln

Q3 Adjusted Operating Margin

16.30%

Q3 Gross Profit

$429.30 mln

Q3 Operating Expenses

$520.30 mln

Q3 Operating Income

-$91 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Bruker Corporation is $62.00, about 9.7% above its November 3 closing price of $56.50

  • The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 27 three months ago


Reuters Recommended Reads

  • Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

  • Nov 3 - AMETEK Q3 sales beat estimates, raises outlook

  • Nov 3 - Zebra Technologies Q3 revenue beats on strong demand across segments


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.